ClinicalTrials.Veeva

Menu

Hypertension Study of Ventavis® Inhalation Therapy in the Treatment of Patients With Pulmonary Arterial Hypertension (VENIS)

Bayer logo

Bayer

Status

Completed

Conditions

Pulmonary Hypertension

Treatments

Drug: Iloprost (Ventavis BAYQ6256)

Study type

Observational

Funder types

Industry

Identifiers

NCT01062282
14184
VENIS
VE0610KR

Details and patient eligibility

About

The purpose of this study is to gain information on safety and efficacy from Korean patients who starting Ventavis treatment by observational method.

Enrollment

41 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • The treating physician has chosen Ventavis as a suitable treatment for the patient
  • Patient with PH and classified as NYHA functional class III or IV and WHO group 1

Exclusion criteria

  • Any condition that prevents participation in the study, including pregnancy and other contraindications for Ventavis treatment (as listed in the current Ventavis patient package insert).

Trial design

41 participants in 1 patient group

Group 1
Treatment:
Drug: Iloprost (Ventavis BAYQ6256)

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems